	US 12,215,348 B2
	Methods for producing genetically engineered cell compositions and related compositions
Mirna Mujacic, Seattle, WA (US); and Ayu Rahardjo, Kirkland, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
Filed on Nov. 10, 2023, as Appl. No. 18/506,851.
Application 18/506,851 is a continuation of application No. 16/637,709, granted, now 11,851,678, previously published as PCT/US2018/046149, filed on Aug. 9, 2018.
Claims priority of provisional application 62/596,770, filed on Dec. 8, 2017.
Claims priority of provisional application 62/543,363, filed on Aug. 9, 2017.
Prior Publication US 2024/0076617 A1, Mar. 7, 2024
Int. Cl. A61K 35/17 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); G01N 33/569 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464417 (2023.05); C12N 7/00 (2013.01); C12N 15/86 (2013.01); G01N 33/56972 (2013.01); A61K 2239/48 (2023.05); C12N 2502/1114 (2013.01); C12N 2740/13043 (2013.01); C12N 2740/15043 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01)]

26 Claims

1. A method of generating a composition of engineered cells, the method comprising:

contacting an input cell composition comprising naïve-like CD4+ T cells and naïve-like CD8+ T cells from a biological sample from a subject with an agent comprising a nucleic acid molecule encoding a recombinant receptor under conditions to introduce the nucleic acid encoding the recombinant receptor into cells in the composition;

wherein the naïve-like CD4+ T cells and the naïve-like CD8+ T cells are surface positive for CD45RA, CD27 and/or CCR7 and are surface negative for CD45RO and/or CD62L;

wherein the ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells present in the input cell composition is between 10:1 and 0.05:1, inclusive; and

wherein the method produces recombinant receptor expressing T cells.